Royce & Associates LP Raises Stake in Omnicell, Inc. (NASDAQ:OMCL)

Royce & Associates LP raised its position in Omnicell, Inc. (NASDAQ:OMCL) by 4.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,417 shares of the company’s stock after acquiring an additional 820 shares during the quarter. Royce & Associates LP’s holdings in Omnicell were worth $864,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its position in shares of Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after buying an additional 273 shares during the last quarter. Van ECK Associates Corp increased its holdings in shares of Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after acquiring an additional 315 shares during the period. First Horizon Advisors Inc. increased its stake in Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after buying an additional 355 shares during the period. KBC Group NV increased its stake in Omnicell by 60.8% in the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock valued at $92,000 after buying an additional 778 shares during the period. Finally, AlphaQuest LLC increased its stake in Omnicell by 307.8% in the 4th quarter. AlphaQuest LLC now owns 3,576 shares of the company’s stock valued at $159,000 after buying an additional 2,699 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on OMCL. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a research note on Thursday, March 6th. Bank of America reduced their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. Wells Fargo & Company reduced their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. JPMorgan Chase & Co. dropped their price objective on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday. Finally, Benchmark reaffirmed a “buy” rating and set a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $51.00.

Omnicell Trading Down 2.7 %

OMCL opened at $33.94 on Friday. The firm has a market capitalization of $1.59 billion, a P/E ratio of 125.71, a P/E/G ratio of 7.53 and a beta of 0.85. The firm’s 50 day moving average is $39.77 and its 200-day moving average is $42.91. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.75. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.